About AbbVie
AbbVie Inc. is a US-based biopharmaceutical company formed in 2013 as a spin-off from Abbott Laboratories. AbbVie is focused on discovering and delivering innovative medicines across immunology, oncology, neuroscience, and eye care.
Key Products
AbbVie built its success on Humira (adalimumab), the world's top-selling drug for over a decade. Following Humira's patent expiration, AbbVie has successfully transitioned to a next-generation portfolio including Skyrizi and Rinvoq in immunology.
Therapeutic Areas
Beyond immunology, AbbVie is a leader in oncology with drugs like Imbruvica and Venclexta. The neuroscience portfolio includes Botox Therapeutics and Vraylar for psychiatric conditions. AbbVie also owns Allergan, adding aesthetics and eye care products.
Research & Development
AbbVie invests approximately $7 billion annually in R&D, with a focus on immunology, oncology, and neuroscience. The company has a robust pipeline with over 50 clinical programs in development.
Global Presence
Headquartered in North Chicago, Illinois, AbbVie employs 50,000+ people worldwide and operates in over 70 countries. The company reported $54.3 billion in revenue in 2023.
Leadership
Richard A. Gonzalez has served as Chairman and CEO since AbbVie's founding in 2013, successfully navigating the company through the Humira patent cliff and building a diversified portfolio.